FDA Asks For ODAC’s Advice On Composite PFS Endpoint for GPC’s Satraplatin
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is seeking the Oncologic Drugs Advisory Committee's opinion on using a composite progression-free survival endpoint as the basis for GPC Biotech's application for Orplatna (satraplatin) to treat androgen-independent prostate cancer in men who failed prior chemotherapy once
You may also be interested in...
ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative
Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.
ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative
Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.
GPC Satraplatin Data Show Reduction In Disease Progression In Prostate Cancer
Data presented at ASCO is part of a Phase III registrational trial for the platinum-based chemotherapy.